Arthur L. Weaver, MD, MS, FACP, MACR
Clinical Professor, Department of Medicine
Division of Rheumatology
University of Nebraska School of Medicine
Physician & Pharmacists: 2, Nursing/NP: 2.4
Until recently, standard pharmacotherapy for the management of spondyloarthropathies was primarily therapeutic doses of nonsteroidal antiinflammatory drugs (NSAIDs). Although these agents can provide some relief of symptoms, they are not considered to be disease-modifying. Promising results have been reported in spondyloarthropathies with the use of disease-modifying antirheumatic drugs (DMARDs) as well as anti-tumor necrosis factor-a therapy.
This online CME program is designed to inform physicians of the results of recent clinical trials utilizing these newer agents, and to increase awareness of the need for early and aggressive intervention in appropriate patients.
. Target Audience
Rheumatologists and other healthcare professionals with an interest in the management of spondyloarthropathies and rheumatoid arthritis.
Upon completion of this educational activity, the participant should be able to:
Discuss the results of recent clinical trials utilizing disease-modifying anti-rheumatic drugs and anti-tumor necrosis factor-a therapy for the management of rheumatoid arthritis and spondyloarthropathies.
Develop strategies for the diagnosis and clinical management of spondyloarthropathies and RA.
Assess the benefits and risks of all agents available for the management of these conditions.
Dr. Weaver has financial interest/relationship or affiliation with one or more organizations including grant research support, consultant status, medical advisory boards and speakers bureaus. These companies include Abbott Laboratories, Abgenix, Inc., Amgen Inc., Aventis Pharmaceuticals, Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Centocor, Inc., Connetics Corporation, Forest Laboratories, Fujisawa Healthcare, Inc., Helsinn Healthcare, Hoffmann-LaRoche, Inc., Immunex Corporation, Eli Lilly & Company, Merck & Co., Inc., Merckel, Novartis Pharmaceuticals Corporation, Ortho McNeil Pharmaceutical, Parke-Davis, Pfizer Inc, Pharmacia & Upjohn, Inc., Proctor and Gamble Pharmaceuticals, Prometheus Laboratories, Inc., TAP Pharmaceuticals, Inc., Takeda Pharmaceuticals America, Inc., Theraquest Biosciences, and Wyeth Pharmaceuticals. Dr. Weaver is also on the board of directors of MGI Pharma and Boston Healthcare.
This course is meant to educate healthcare professionals regarding currently approved treatments and those that may be available in the future, off-label use will be discussed.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Consultant and Medical Communications Media, Incorporated. AKH Consultant is accredited by the ACCME to provide continuing medical education for physicians.
AKH Consultant designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he or she actually spent in the activity.
AKH Consultant is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education.
This program has been assigned the Universal Program Number 077-999-03-034-H01 and is acceptable for 2.0 contact hours (0.2 CEUs) in states that recognize ACPE-approved providers.
AKH Consultant is approved as a provider of nursing and nurse practitioner continuing education by the American Academy of Nurse Practitioners. Provider #030803. This program has been approved for 2.4 contact hours.
AKH Consultant is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation, and is an approved provider through the Boards of Nursing in CA, #CEP12070, & IA, #277. This program has been approved for 2.4 nursing contact hours.
Participants must complete post-test and evaluation to receive credit. Certificates will be issued within 2-3 weeks of AKH Consultant receipt.
AAPA accepts Category I CME credit for the PRA from organizations accredited by ACCME. All programs on cmecorner.com which carry ACCME Category I CME credit are acceptable towards the PA Category I (Preapproved) CME requirement. PAs requesting credit should check the “Physician” box on the post-test.
Commercial Support Statements
Made possible through an unrestricted educational grant from
Amgen and Wyeth Pharmaceuticals.
This program is also offered as an interactive CD-ROM. Physicians, pharmacists and nurses who received credit through completion of the CD-ROM version are not eligible to receive continuing education credit through this online program.
Estimated completion time: 110 minutes.
Clicking on "start the program" on this screen will begin the program presentation.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen.
Click on the "Start program" icon.
The next screen will permit you to check for or download the Flash player required to run this program. You will also find buttons that will permit you to start the program presentation, access other program elements, and take the post-test.
The information contained in this program does not necessarily reflect the opinions or recommendations of AKH Consultant, Amgen, Wyeth Pharmaceuticals, or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.